Does the media favor LNTH or MRVI?

In the previous week, Lantheus had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Maravai LifeSciences. Lantheus' average media sentiment score of 0.71 beat Maravai LifeSciences' score of 0.63 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRVI or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for PTC Therapeutics and 4 mentions for Maravai LifeSciences. PTC Therapeutics' average media sentiment score of 0.77 beat Maravai LifeSciences' score of 0.63 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Scholar Rock and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.63 beat Scholar Rock's score of 0.19 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor COGT or MRVI?

In the previous week, Maravai LifeSciences had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Maravai LifeSciences and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.67 beat Maravai LifeSciences' score of 0.63 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or XENE?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 4 mentions for Maravai LifeSciences. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Maravai LifeSciences' score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$7.10 +0.11 (+1.57%)

Closing price 07/21/2026 04:00 PM Eastern

Extended Trading

$7.05 -0.05 (-0.70%)

As of 04:33 AM Eastern

Compare

MRVI vs. LNTH, PTCT, SRRK, COGT, and XENE

Should you buy Maravai LifeSciences stock or one of its competitors? MarketBeat compares Maravai LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maravai LifeSciences include Lantheus (LNTH), PTC Therapeutics (PTCT), Scholar Rock (SRRK), Cogent Biosciences (COGT), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Maravai LifeSciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Lantheus has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.56	$233.56M	$4.15	26.01
Maravai LifeSciences	$204.73M	8.95	-$130.77M	-$0.71	N/A

In the previous week, Lantheus had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Maravai LifeSciences. Lantheus' average media sentiment score of 0.71 beat Maravai LifeSciences' score of 0.63 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus presently has a consensus target price of $110.43, indicating a potential upside of 2.30%. Maravai LifeSciences has a consensus target price of $5.50, indicating a potential downside of 22.54%. Given Lantheus' stronger consensus rating and higher probable upside, analysts plainly believe Lantheus is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Maravai LifeSciences' net margin of -51.07%. Lantheus' return on equity of 29.32% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

Lantheus beats Maravai LifeSciences on 13 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to PTC Therapeutics?

Maravai LifeSciences (NASDAQ:MRVI) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

PTC Therapeutics has a net margin of -22.58% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maravai LifeSciences has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Maravai LifeSciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	8.95	-$130.77M	-$0.71	N/A
PTC Therapeutics	$1.73B	3.76	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for PTC Therapeutics and 4 mentions for Maravai LifeSciences. PTC Therapeutics' average media sentiment score of 0.77 beat Maravai LifeSciences' score of 0.63 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences presently has a consensus price target of $5.50, suggesting a potential downside of 22.54%. PTC Therapeutics has a consensus price target of $92.29, suggesting a potential upside of 17.56%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

PTC Therapeutics beats Maravai LifeSciences on 11 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Scholar Rock?

Maravai LifeSciences (NASDAQ:MRVI) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Maravai LifeSciences has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Maravai LifeSciences presently has a consensus target price of $5.50, suggesting a potential downside of 22.54%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 10.06%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Maravai LifeSciences has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	8.95	-$130.77M	-$0.71	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Scholar Rock has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Scholar Rock	N/A	-163.52%	-96.67%

In the previous week, Scholar Rock had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Scholar Rock and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.63 beat Scholar Rock's score of 0.19 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scholar Rock beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

50.3% of Maravai LifeSciences shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Maravai LifeSciences	$204.73M	8.95	-$130.77M	-$0.71	N/A

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

In the previous week, Maravai LifeSciences had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Maravai LifeSciences and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.67 beat Maravai LifeSciences' score of 0.63 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences currently has a consensus target price of $45.90, suggesting a potential upside of 15.79%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential downside of 22.54%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Cogent Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Maravai LifeSciences beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Maravai LifeSciences (NASDAQ:MRVI) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Maravai LifeSciences has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Maravai LifeSciences has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	8.95	-$130.77M	-$0.71	N/A
Xenon Pharmaceuticals	$7.50M	860.23	-$345.91M	-$4.70	N/A

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 4 mentions for Maravai LifeSciences. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Maravai LifeSciences' score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential downside of 22.54%. Xenon Pharmaceuticals has a consensus target price of $77.20, suggesting a potential upside of 15.67%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.80B	$8.72B	$6.80B	$12.31B
Dividend Yield	N/A	2.48%	2.67%	9.67%
P/E Ratio	-10.00	15.40	26.93	24.18
Price / Sales	8.95	7.89	488.60	79.77
Price / Cash	16.70	18.24	49.71	59.37
Price / Book	4.86	3.25	10.67	6.25
Net Income	-$130.77M	$230.22M	$3.60B	$331.66M
7 Day Performance	0.85%	-1.41%	-1.01%	-1.32%
1 Month Performance	35.24%	-0.15%	1.58%	-1.74%
1 Year Performance	180.63%	-2.37%	24.13%	18.04%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.5631 of 5 stars	$7.10 +1.6%	$5.50 -22.5%	+198.3%	$1.80B	$204.73M	N/A	610
LNTH Lantheus	2.5793 of 5 stars	$102.66 -2.6%	$108.29 +5.5%	+50.9%	$6.67B	$1.54B	24.68	1,193
PTCT PTC Therapeutics	3.5918 of 5 stars	$80.07 -1.5%	$91.57 +14.4%	+64.0%	$6.63B	$1.73B	N/A	1,410	Analyst Forecast
SRRK Scholar Rock	2.202 of 5 stars	$54.25 -0.8%	$56.00 +3.2%	+23.7%	$6.49B	N/A	N/A	140	Analyst Forecast
COGT Cogent Biosciences	1.7324 of 5 stars	$38.03 +1.5%	$43.73 +15.0%	+222.3%	$6.46B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. LNTH, PTCT, SRRK, COGT, and XENE

How does Maravai LifeSciences compare to Lantheus?

Summary

How does Maravai LifeSciences compare to PTC Therapeutics?

Summary

How does Maravai LifeSciences compare to Scholar Rock?

Summary

How does Maravai LifeSciences compare to Cogent Biosciences?

Summary

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. LNTH, PTCT, SRRK, COGT, and XENE

How does Maravai LifeSciences compare to Lantheus?

Which has higher earnings and valuation, LNTH or MRVI?

Does the media favor LNTH or MRVI?

Do analysts rate LNTH or MRVI?

Do institutionals and insiders believe in LNTH or MRVI?

Is LNTH or MRVI more profitable?

Which has more risk & volatility, LNTH or MRVI?

Summary

How does Maravai LifeSciences compare to PTC Therapeutics?

Is MRVI or PTCT more profitable?

Do institutionals & insiders believe in MRVI or PTCT?

Which has more risk and volatility, MRVI or PTCT?

Which has better earnings and valuation, MRVI or PTCT?

Does the media prefer MRVI or PTCT?

Do analysts rate MRVI or PTCT?

Summary

How does Maravai LifeSciences compare to Scholar Rock?

Which has more risk & volatility, MRVI or SRRK?

Do analysts rate MRVI or SRRK?

Which has better valuation and earnings, MRVI or SRRK?

Do institutionals and insiders hold more shares of MRVI or SRRK?

Is MRVI or SRRK more profitable?

Does the media refer more to MRVI or SRRK?

Summary

How does Maravai LifeSciences compare to Cogent Biosciences?

Do institutionals & insiders believe in COGT or MRVI?

Which has better earnings and valuation, COGT or MRVI?

Which has more risk and volatility, COGT or MRVI?

Is COGT or MRVI more profitable?

Does the media favor COGT or MRVI?

Do analysts rate COGT or MRVI?

Summary

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Which has more risk and volatility, MRVI or XENE?

Which has preferable earnings & valuation, MRVI or XENE?

Do institutionals and insiders hold more shares of MRVI or XENE?

Is MRVI or XENE more profitable?

Does the media refer more to MRVI or XENE?

Do analysts prefer MRVI or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools